Clinically, colonic PAD4 mRNA levels correlate with disease activity and cytokine production in UC and with disease severity and pro-inflammatory responses in CD [286], reinforcing PAD4 inhibition as a promising approach across IBD subtypes. This evidence concerns the gene PADI4 and inflammatory bowel disease.